Lercanidipina Pentafarma

Lercanidipine Hydrochloride, the active ingredient in Lercanidipina Pentafarma, is a calcium channel blocker presented as an oral tablet for oral use. It treats hypertension in adult patients by lowering elevated blood pressure. GNH USA supplies Lercanidipina Pentafarma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercanidipine is a dihydropyridine calcium‑channel blocker used to manage high blood pressure. - Essential hypertension: reduces systolic and diastolic pressure, helping to prevent cardiovascular complications. - Isolated systolic hypertension: lowers elevated systolic values, improving arterial compliance. - Mild to moderate hypertension: provides consistent blood pressure control when lifestyle measures are insufficient.

Lercanidipine is generally well tolerated, but several adverse reactions have been reported.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Flushing: warm sensation and reddening of the skin. - Peripheral edema: swelling of ankles or lower legs. - Dizziness or light‑headedness, especially after standing. - Tachycardia: increased heart rate. - Palpitations: awareness of heartbeat.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure causing fainting. - Myocardial infarction: rare occurrence of heart attack. - Hepatic dysfunction: abnormal liver enzyme elevations. - Allergic reactions: rash, itching, or urticaria. - Angioedema: swelling of face, lips, or throat. - Cardiac arrhythmias: irregular heart rhythms.

Before initiating therapy, clinicians should assess patient‑specific factors and monitor for potential risks. - Renal impairment: adjust therapy if severe renal dysfunction is present. - Hepatic impairment: use with caution in patients with liver disease. - Concomitant strong CYP3A4 inhibitors: may increase plasma levels, requiring dose adjustment. - Pregnancy: avoid unless clearly needed; safety data are limited. - Elderly patients: start at low dose and monitor for orthostatic hypotension. - Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture and light.

Lercanidipine may interact with several drug classes, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase lercanidipine exposure. - Grapefruit juice: can markedly raise plasma concentrations. - Co‑administration with other potent antihypertensives: risk of excessive hypotension.

Moderate Interactions (Monitor Closely):\n- Diuretics: may enhance antihypertensive effect, monitor electrolytes. - Beta‑blockers: additive blood pressure lowering, watch for bradycardia. - NSAIDs: may attenuate antihypertensive response, assess blood pressure regularly.